ArticleEnvironmental microbiology reports2026
Bioprospecting Indoor Bacteria Producing Bioactive Metabolites.
Article in Environmental microbiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New biomolecules are prospected for new antimicrobial, antiparasitic and cytostatic drugs. Here, we present bioassay-guided methods for prospecting indoor bacteria producing non-protein antibiotic molecules. Out of 650 bacterial colonies tested, 108 antimicrobial isolates representing 15 species and cryptic Actinobacteria, produced non-protein antibiotics affecting mammalian cells. Methanol extracts of the 108 strains tested with a battery of bioassays revealed four toxicity endpoints: (1) Cell death (CD). (2) Boar sperm motility inhibition (BSMI). (3) Inhibition of cell proliferation (ICP). (4) Mitochondrial toxicity (MT). The battery of endpoints divided the 108 strains into four toxicity profiles: Profile I: Lethal toxins (42 strains). Positive controls: Alamethicin, a channel forming ionophore and a biosurfactant surfactin. Profile II: Sublethal mitochondrial toxins (51 strains). Positive controls: The mitochondrial toxins valinomycin and antimycin A. Profile III: Sublethal cytostatic toxins (7 strains). Positive control: Chaetoglobosin A, a glucose transport inhibitor. Profile IV: Cytostatic toxins (8 strains). Positive controls: Actinomycin D, RNA syntesis inhibitor. Strains of Bacillus, Streptomyces and Paenibacillus produced amylosin, cereulide, surfactins, lichenysins, iturins, fengysin, valinomycin and fusarisidins. Strains of Peribacillus Lysinibacillus, Microbacterium, Nocardiopsis and cryptic Actnobacteria produced possible novel bioactive molecules. The indoor environments were easily accessible habitats for bacteria producing ionophores, surfactants, and mitochondrial toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.